Novo Nordisk Taps Eurofarma to Launch Two Weekly Semaglutide Brands in Brazil

Overview

• The companies announced a partnership that makes Eurofarma the exclusive distributor responsible for commercialization and promotion in Brazil.
• Two weekly injectable brands are covered: Poviztra for obesity and overweight with comorbidities, and a type 2 diabetes brand reported as Extensior or Extension.
• Both medicines are projected by the companies to reach the Brazilian market in October, with rollout and commercialization to follow.
• Novo Nordisk brings the product and research expertise, while Eurofarma contributes national distribution capabilities and on-the-ground commercial reach.
• The tie-up follows intensifying competition that includes Eli Lilly’s Mounjaro launch in June, and specialists say expanded supply could extend access to more cities and help ease prices.